M&A Deal Summary

Boston Scientific Acquires Apollo Endosurgery

On November 29, 2022, Boston Scientific acquired life science company Apollo Endosurgery for 615M USD

Acquisition Highlights
  • This is Boston Scientific’s 6th transaction in the Life Science sector.
  • This is Boston Scientific’s 10th largest (disclosed) transaction.
  • This is Boston Scientific’s 46th transaction in the United States.
  • This is Boston Scientific’s 1st transaction in Texas.

M&A Deal Summary
Date 2022-11-29
Target Apollo Endosurgery
Sector Life Science
Buyer(s) Boston Scientific
Deal Type Add-on Acquisition
Deal Value 615M USD
Advisor(s) Piper Sandler & Co. (Financial)
Cooley (Legal)

Target

Apollo Endosurgery

Austin, Texas, United States
Apollo Endosurgery is a developer of therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. The company concluded mid-stage clinical development of drug candidates iSONEP™ (sphingomab) in wet age-related macular degeneration and ASONEP™ (anti-S1P antibody for systemic delivery) in renal cell carcinoma in 2015. Apollo Endosurgery was incorporated in 2005 and is based in Austin, Texas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Boston Scientific

Marlborough, Massachusetts, United States
Category Company
Founded 1979
Sector Medical Products
Employees48,000
Revenue 14.2B USD (2023)
DESCRIPTION
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.

Boston Scientific is a medical technology company. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. Boston Scientific was founded in 1979 and is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 60 of 65
Sector (Life Science) 6 of 6
Type (Add-on Acquisition) 47 of 50
State (Texas) 1 of 1
Country (United States) 46 of 50
Year (2022) 3 of 4
Size (of disclosed) 10 of 34
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-15 Obsidio

Columbia, South Carolina, United States

Obsidio is a privately-held company that has developed the Gel Embolic Material technology used for embolization of blood vessels in the peripheral vasculature. Obsidio is based in Columbia, South Carolina.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-11 Acotec

Beijing, China

Acotec is a medical technology company that offers solutions designed for a variety of interventional procedures in innovative medical solutions, including drug-coated balloons (DCBs), which are used in the treatment of vascular and other diseases. In 2016, the company launched the first peripheral DCB in China after receiving approval from the National Medical Products Administration. The Acotec portfolio also includes radiofrequency ablation technologies and thrombus aspiration catheters, as well as more than 20 other products in various stages of development across a range of specialties. Acotec was incorporated in 2020 and is headquartered in Beijing, China.

Buy -
Mergr

Product

Company

Legal